Literature DB >> 14610105

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.

Andrew R Pachner1, Joel Oger, Jacqueline Palace.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14610105     DOI： 10.1212/01.wnl.0000092359.93813.92

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

Review 1.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 2.  Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Authors:  Hans-P Hartung; Chris Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew Pachner; Huub Schellekens; Finn Sellebjerg; Krysztof Selmaj; Per Soelberg Sorensen
Journal:  J Neurol       Date:  2007-04-24       Impact factor: 4.849

3.  Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.

Authors:  Paul I Creeke; Rachel A Farrell
Journal:  Ther Adv Neurol Disord       Date:  2013-01       Impact factor: 6.570

4.  The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.

Authors:  Agnieszka Wencel-Warot; Slawomir Michalak; Marcin Warot; Alicja Kalinowska-Lyszczarz; Radoslaw Kazmierski
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.